More NewsRead More
Mirati Therapeutics Reports Second Quarter 2015 Financial Results and Provides Business Update
August 06, 2015
Mirati Therapeutics And MedImmune Partner On Immuno-Oncology Combination In Lung Cancer
August 05, 2015
Initial Data from Ongoing Expansion Study of MGCD265 Show Preliminary Evidence of Clinical Efficacy in Heavily Pretreated Non-Small Cell Lung Cancer (NSCLC) Patients with MET Gene Alterations
May 30, 2015
Mirati Therapeutics to Provide Updates on Pipeline Programs at 2015 ASCO Annual Meeting
May 13, 2015
from Dividend Channel
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here